Neuphoria Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 8, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Cap	25	14	10	18	53	-
Market Cap Growth	142.77%	38.31%	-43.43%	-65.84%	-	-
Enterprise Value	5.83	-0.16	-2.33	6.09	29.78	0
Last Close Price	4.67	7.10	9.20	26.40	83.88	-
PS Ratio	-1902.41	0.90	-	-	-	-
PB Ratio	0.85	0.74	0.58	0.82	1.34	-
P/TBV Ratio	0.56	0.61	0.44	0.82	1.34	-
P/FCF Ratio	-	181.89	-	-	-	-
P/OCF Ratio	-	181.89	-	-	-	-
EV/Sales Ratio	-	-0.01	-	-	-	-
EV/EBITDA Ratio	-	0.35	0.14	-	2.52	-
EV/EBIT Ratio	-	0.14	0.13	-	2.70	-
EV/FCF Ratio	-	-	0.16	-	-	-
Debt / Equity Ratio	-	0	0.01	0.01	0.01	0.01
Debt / EBITDA Ratio	-	-	-	-	0.04	0.12
Debt / FCF Ratio	-	1.51	-	-	-	-
Net Debt / Equity Ratio	-0.66	-0.74	-0.71	-0.53	-0.58	-0.58
Net Debt / EBITDA Ratio	1.21	30.23	0.72	0.55	-1.92	-3.70
Net Debt / FCF Ratio	1.13	-182.50	0.84	0.83	1.51	3.67
Asset Turnover	0.00	0.56	0	0	0	0
Quick Ratio	13.91	3.37	3.33	4.57	10.00	12.07
Current Ratio	14.31	3.56	3.45	4.87	12.46	13.10
Return on Equity (ROE)	-58.96%	-2.03%	-78.44%	-69.80%	-40.05%	-29.35%
Return on Assets (ROA)	-45.96%	-1.77%	-63.30%	-59.34%	25.52%	13.12%
Return on Invested Capital (ROIC)	-121.26%	-3.53%	-118.90%	-117.28%	53.08%	19.65%
Return on Capital Employed (ROCE)	-49.80%	-4.69%	-72.08%	-64.13%	27.03%	15.16%
FCF Yield	-	0.55%	-	-	-	-
Buyback Yield / Dilution	-161.08%	-95.01%	-22.38%	-8.53%	-73.52%	99.93%
Total Shareholder Return	-161.08%	-95.01%	-22.38%	-8.53%	-73.52%	99.93%

SEC Filings: 10-K · 10-Q